548472-49-7

Basic information

• Product Name: 1H-IMidazole, 4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-Methoxy-2-(1-Methylethoxy)phenyl]-, (4R,5S)-rel-
• Synonyms: 1H-IMidazole, 4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-Methoxy-2-(1-Methylethoxy)phenyl]-, (4R,5S)-rel-;rel-(4R,5S)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole
• CAS NO: 548472-49-7
• Molecular Formula: C₂₅H₂₄Cl₂N₂O₂
• Molecular Weight: 455.38
• Mol File: 548472-49-7.mol

Chemical Properties

• Boiling Point: 576.0±60.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• PKA: 8.13±0.70(Predicted)
• CAS DataBase Reference: 1H-IMidazole, 4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-Methoxy-2-(1-Methylethoxy)phenyl]-, (4R,5S)-rel-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-IMidazole, 4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-Methoxy-2-(1-Methylethoxy)phenyl]-, (4R,5S)-rel-(548472-49-7)
• EPA Substance Registry System: 1H-IMidazole, 4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-Methoxy-2-(1-Methylethoxy)phenyl]-, (4R,5S)-rel-(548472-49-7)

Safety Data

• Hazardous Substances Data: 548472-49-7(Hazardous Substances Data)

Usage

Purpose

Targeted therapy medication for treating certain types of cancer (e.g., melanoma with specific genetic mutations)

Mechanism of Action

Inhibits the activity of proteins that promote cancer growth and spread

Administration

Orally in the form of tablets

Safety Precautions

Usage and handling should only be conducted by trained professionals in a controlled environment due to potential toxicity.

Upstream product

• 86212-34-2 (1R,2S)-1,2-bis(4-chlorophenyl)ethane-1,2-diamine 
• 107811-48-3 2-isopropoxy-4-methoxybenzene-1-carboaldehyde 
• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 
• 104-88-1 4-chlorobenzaldehyde 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 115294-32-1 C₂₈H₂₀Cl₄N₂O 

Relevant articles and documents

Dimer amide micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase

The invention provides dimer amide micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase. The structure of the PROTACs is shown in the specification, wherein in a compound (I), L1 is C1-C30 linear or branched alkyl with or without a substituent group, and any carbon atom in L1 is optionally replaced by heteroatom; R1, R2, R3 and R4 are C1-C30 linear or branched alkyl with orwithout a substituent group, C1-C30 aryl with or without a substituent group, C1-C30 linear or branched alkylaryl with or without a substituent group or C1-C30 linear or branched aryl alkyl with or without a substituent group respectively and independently; X1, X2, X3 and X4 are halogen respectively and independently.

Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics

We have developed a heterobifunctional all-small molecule PROTAC (PROteolysis TArgeting Chimera) capable of inducing proteasomal degradation of the androgen receptor. This cell permeable PROTAC consists of a non-steroidal androgen receptor ligand (SARM) and the MDM2 ligand known as nutlin, connected by a PEG-based linker. The SARM-nutlin PROTAC recruits the androgen receptor to MDM2, which functions as an E3 ubiquitin ligase. This leads to the ubiquitination of the androgen receptor, and its subsequent degradation by the proteasome. Upon treatment of HeLa cells with 10 μM PROTAC for 7 h, we were able to observe a decrease in androgen receptor levels. This degradation is proteasome dependent, as it is mitigated in cells pre-treated with 10 μM epoxomicin, a specific proteasome inhibitor. These results have implications for the potential study and treatment of various cancers with increased androgen receptor levels.